Makers Laboratories（506919）株式概要総合製薬会社であるメイカーズ・ラボラトリーズ社は、インドで製剤を製造・販売している。 詳細506919 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より85.7%で取引されている リスク分析意味のある時価総額がありません ( ₹925M )Indian市場と比較した過去 3 か月間の株価の変動利益率(1.7%)は昨年より低い(6.2%) すべてのリスクチェックを見る506919 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹156.8539.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-63m2b2016201920222025202620282031Revenue ₹1.9bEarnings ₹30.6mAdvancedSet Fair ValueView all narrativesMakers Laboratories Limited 競合他社Vaishali PharmaSymbol: NSEI:VAISHALIMarket cap: ₹931.5mConcord DrugsSymbol: BSE:538965Market cap: ₹1.0bCuris LifesciencesSymbol: NSEI:CURISMarket cap: ₹905.1mAmwill Health CareSymbol: BSE:544353Market cap: ₹837.0m価格と性能株価の高値、安値、推移の概要Makers Laboratories過去の株価現在の株価₹156.8552週高値₹186.7052週安値₹109.00ベータ0.101ヶ月の変化0.38%3ヶ月変化2.18%1年変化1.82%3年間の変化42.27%5年間の変化-23.43%IPOからの変化335.69%最新ニュースReported Earnings • May 27Full year 2026 earnings released: EPS: ₹3.99 (vs ₹12.70 in FY 2025)Full year 2026 results: EPS: ₹3.99 (down from ₹12.70 in FY 2025). Revenue: ₹1.42b (up 18% from FY 2025). Net income: ₹23.5m (down 69% from FY 2025). Profit margin: 1.7% (down from 6.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.お知らせ • May 06Makers Laboratories Limited to Report Q4, 2026 Results on May 26, 2026Makers Laboratories Limited announced that they will report Q4, 2026 results on May 26, 2026New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹922.5m market cap, or US$9.88m). Minor Risk Profit margins are more than 30% lower than last year (0.9% net profit margin).New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹871.2m market cap, or US$9.61m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).Reported Earnings • Feb 11Third quarter 2026 earnings released: EPS: ₹1.59 (vs ₹0.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹1.59 (up from ₹0.50 loss in 3Q 2025). Revenue: ₹356.7m (up 29% from 3Q 2025). Net income: ₹9.38m (up ₹12.3m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 21Makers Laboratories Limited to Report Q3, 2026 Results on Feb 10, 2026Makers Laboratories Limited announced that they will report Q3, 2026 results on Feb 10, 2026最新情報をもっと見るRecent updatesReported Earnings • May 27Full year 2026 earnings released: EPS: ₹3.99 (vs ₹12.70 in FY 2025)Full year 2026 results: EPS: ₹3.99 (down from ₹12.70 in FY 2025). Revenue: ₹1.42b (up 18% from FY 2025). Net income: ₹23.5m (down 69% from FY 2025). Profit margin: 1.7% (down from 6.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.お知らせ • May 06Makers Laboratories Limited to Report Q4, 2026 Results on May 26, 2026Makers Laboratories Limited announced that they will report Q4, 2026 results on May 26, 2026New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹922.5m market cap, or US$9.88m). Minor Risk Profit margins are more than 30% lower than last year (0.9% net profit margin).New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹871.2m market cap, or US$9.61m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).Reported Earnings • Feb 11Third quarter 2026 earnings released: EPS: ₹1.59 (vs ₹0.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹1.59 (up from ₹0.50 loss in 3Q 2025). Revenue: ₹356.7m (up 29% from 3Q 2025). Net income: ₹9.38m (up ₹12.3m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 21Makers Laboratories Limited to Report Q3, 2026 Results on Feb 10, 2026Makers Laboratories Limited announced that they will report Q3, 2026 results on Feb 10, 2026New Risk • Nov 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹748.2m market cap, or US$8.44m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹0.20 loss per share (vs ₹14.94 profit in 2Q 2025)Second quarter 2026 results: ₹0.20 loss per share (down from ₹14.94 profit in 2Q 2025). Revenue: ₹345.3m (up 17% from 2Q 2025). Net loss: ₹1.17m (down 101% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Oct 16Makers Laboratories Limited to Report Q2, 2026 Results on Nov 07, 2025Makers Laboratories Limited announced that they will report Q2, 2026 results on Nov 07, 2025Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.74 (vs ₹1.67 loss in 1Q 2025)First quarter 2026 results: EPS: ₹0.74 (up from ₹1.67 loss in 1Q 2025). Revenue: ₹352.7m (up 19% from 1Q 2025). Net income: ₹4.37m (up ₹14.2m from 1Q 2025). Profit margin: 1.2% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.New Risk • Jul 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹867.9m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$10m (₹867.9m market cap, or US$9.99m). Minor Risk Large one-off items impacting financial results.お知らせ • Jul 25Makers Laboratories Limited to Report Q1, 2026 Results on Aug 08, 2025Makers Laboratories Limited announced that they will report Q1, 2026 results at 9:15 AM, Indian Standard Time on Aug 08, 2025Reported Earnings • Jul 10Full year 2025 earnings released: EPS: ₹12.70 (vs ₹10.62 loss in FY 2024)Full year 2025 results: EPS: ₹12.70 (up from ₹10.62 loss in FY 2024). Revenue: ₹1.21b (up 16% from FY 2024). Net income: ₹74.9m (up ₹137.5m from FY 2024). Profit margin: 6.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 02Makers Laboratories Limited, Annual General Meeting, Aug 08, 2025Makers Laboratories Limited, Annual General Meeting, Aug 08, 2025, at 12:30 Indian Standard Time.New Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹850.2m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$10m (₹850.2m market cap, or US$9.80m).Reported Earnings • May 28Full year 2025 earnings released: EPS: ₹12.70 (vs ₹10.62 loss in FY 2024)Full year 2025 results: EPS: ₹12.70 (up from ₹10.62 loss in FY 2024). Revenue: ₹1.33b (up 27% from FY 2024). Net income: ₹74.9m (up ₹137.5m from FY 2024). Profit margin: 5.6% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.New Risk • May 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹814.5m market cap, or US$9.52m).Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹165, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 2.1% over the past three years.お知らせ • May 13Makers Laboratories Limited to Report Q4, 2025 Results on May 26, 2025Makers Laboratories Limited announced that they will report Q4, 2025 results at 9:15 AM, Indian Standard Time on May 26, 2025Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹126, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total loss to shareholders of 28% over the past three years.New Risk • Feb 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹856.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (₹856.4m market cap, or US$9.85m).Reported Earnings • Jan 31Third quarter 2025 earnings released: ₹0.50 loss per share (vs ₹2.61 loss in 3Q 2024)Third quarter 2025 results: ₹0.50 loss per share (improved from ₹2.61 loss in 3Q 2024). Revenue: ₹276.9m (up 4.4% from 3Q 2024). Net loss: ₹2.97m (loss narrowed 81% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Jan 14Makers Laboratories Limited to Report Q3, 2025 Results on Jan 29, 2025Makers Laboratories Limited announced that they will report Q3, 2025 results on Jan 29, 2025Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹219, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past three years.New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹976.5m market cap, or US$11.5m).Reported Earnings • Oct 30Second quarter 2025 earnings released: EPS: ₹14.94 (vs ₹2.27 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹14.94 (up from ₹2.27 loss in 2Q 2024). Revenue: ₹400.8m (up 60% from 2Q 2024). Net income: ₹88.2m (up ₹101.6m from 2Q 2024). Profit margin: 22% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Oct 17Makers Laboratories Limited to Report Q2, 2025 Results on Oct 29, 2024Makers Laboratories Limited announced that they will report Q2, 2025 results on Oct 29, 2024New Risk • Oct 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹806.6m (US$9.61m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 54% per year over the past 5 years. Market cap is less than US$10m (₹806.6m market cap, or US$9.61m).New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 54% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹888.0m market cap, or US$10.6m).New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 54% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₹989.8m market cap, or US$11.8m).お知らせ • Jul 22Makers Laboratories Limited to Report Q1, 2025 Results on Aug 06, 2024Makers Laboratories Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 06, 2024Reported Earnings • Jul 13Full year 2024 earnings released: ₹10.62 loss per share (vs ₹7.90 loss in FY 2023)Full year 2024 results: ₹10.62 loss per share (further deteriorated from ₹7.90 loss in FY 2023). Revenue: ₹1.04b (up 3.1% from FY 2023). Net loss: ₹62.6m (loss widened 32% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.お知らせ • Jul 06Makers Laboratories Limited, Annual General Meeting, Aug 06, 2024Makers Laboratories Limited, Annual General Meeting, Aug 06, 2024, at 11:30 Indian Standard Time.Reported Earnings • May 24Full year 2024 earnings released: ₹10.62 loss per share (vs ₹7.90 loss in FY 2023)Full year 2024 results: ₹10.62 loss per share (further deteriorated from ₹7.90 loss in FY 2023). Revenue: ₹1.06b (up 4.6% from FY 2023). Net loss: ₹62.6m (loss widened 32% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.お知らせ • May 09Makers Laboratories Limited to Report Q4, 2024 Results on May 23, 2024Makers Laboratories Limited announced that they will report Q4, 2024 results on May 23, 2024お知らせ • Feb 15Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024Makers Laboratories Limited announced the resignation of Ms. Surbhi Sharma as Company Secretary /Compliance Officer. Date of Cessation is March 13, 2024.Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹2.61 loss per share (vs ₹3.65 loss in 3Q 2023)Third quarter 2024 results: ₹2.61 loss per share (improved from ₹3.65 loss in 3Q 2023). Revenue: ₹268.8m (up 35% from 3Q 2023). Net loss: ₹15.4m (loss narrowed 30% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.お知らせ • Jan 23Makers Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024Makers Laboratories Limited announced that they will report Q3, 2024 results at 12:15 PM, Indian Standard Time on Feb 13, 2024Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Additional Non-Executive Independent Director Vishal Jain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 09Second quarter 2024 earnings released: ₹2.27 loss per share (vs ₹1.00 loss in 2Q 2023)Second quarter 2024 results: ₹2.27 loss per share (further deteriorated from ₹1.00 loss in 2Q 2023). Revenue: ₹250.6m (down 5.4% from 2Q 2023). Net loss: ₹13.4m (loss widened 108% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.お知らせ • Oct 20Makers Laboratories Limited to Report Q2, 2023 Results on Nov 07, 2023Makers Laboratories Limited announced that they will report Q2, 2023 results on Nov 07, 2023Reported Earnings • Aug 16First quarter 2024 earnings released: ₹3.55 loss per share (vs ₹2.82 loss in 1Q 2023)First quarter 2024 results: ₹3.55 loss per share (further deteriorated from ₹2.82 loss in 1Q 2023). Revenue: ₹252.5m (flat on 1Q 2023). Net loss: ₹21.0m (loss widened 30% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.お知らせ • Jul 26Makers Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023Makers Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023Reported Earnings • Jul 13Full year 2023 earnings released: ₹7.90 loss per share (vs ₹10.13 profit in FY 2022)Full year 2023 results: ₹7.90 loss per share (down from ₹10.13 profit in FY 2022). Revenue: ₹1.01b (down 21% from FY 2022). Net loss: ₹47.5m (down 195% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.お知らせ • Jul 06Makers Laboratories Limited, Annual General Meeting, Aug 14, 2023Makers Laboratories Limited, Annual General Meeting, Aug 14, 2023, at 11:30 Indian Standard Time.Reported Earnings • May 24Full year 2023 earnings released: ₹7.90 loss per share (vs ₹10.13 profit in FY 2022)Full year 2023 results: ₹7.90 loss per share (down from ₹10.13 profit in FY 2022). Revenue: ₹1.04b (down 19% from FY 2022). Net loss: ₹47.5m (down 195% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.Reported Earnings • Feb 14Third quarter 2023 earnings released: ₹3.65 loss per share (vs ₹4.13 profit in 3Q 2022)Third quarter 2023 results: ₹3.65 loss per share (down from ₹4.13 profit in 3Q 2022). Revenue: ₹201.4m (down 32% from 3Q 2022). Net loss: ₹22.1m (down 209% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.お知らせ • Jan 21Makers Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023Makers Laboratories Limited announced that they will report Q3, 2023 results on Feb 13, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹1.00 loss per share (vs ₹3.54 profit in 2Q 2022)Second quarter 2023 results: ₹1.00 loss per share (down from ₹3.54 profit in 2Q 2022). Revenue: ₹273.8m (down 18% from 2Q 2022). Net loss: ₹6.44m (down 137% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year.お知らせ • Nov 01Makers Laboratories Limited Announces Resignation of Rinku Kholakiya as Company SecretaryMakers Laboratories Limited informed that Ms. Rinku Kholakiya, Company Secretary has resigned from the services of the Company with effect from close of business hours on 31st October, 2022 and accordingly, she will cease to be the Company Secretary and Key Managerial Personnel of the company from 1st November, 2022.お知らせ • Oct 20Makers Laboratories Limited to Report Q2, 2022 Results on Nov 14, 2022Makers Laboratories Limited announced that they will report Q2, 2022 results on Nov 14, 2022Reported Earnings • Aug 14First quarter 2023 earnings released: ₹2.82 loss per share (vs ₹3.69 profit in 1Q 2022)First quarter 2023 results: ₹2.82 loss per share (down from ₹3.69 profit in 1Q 2022). Revenue: ₹264.6m (down 27% from 1Q 2022). Net loss: ₹16.2m (down 189% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 30Makers Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Makers Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022Reported Earnings • Jul 16Full year 2022 earnings released: EPS: ₹10.12 (vs ₹0.67 loss in FY 2021)Full year 2022 results: EPS: ₹10.12 (up from ₹0.67 loss in FY 2021). Revenue: ₹1.30b (up 89% from FY 2021). Net income: ₹49.8m (up ₹53.1m from FY 2021). Profit margin: 3.8% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 09Makers Laboratories Limited, Annual General Meeting, Aug 12, 2022Makers Laboratories Limited, Annual General Meeting, Aug 12, 2022, at 11:30 Indian Standard Time.お知らせ • May 17Makers Laboratories Limited to Report Q4, 2022 Results on May 27, 2022Makers Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹4.13 (up from ₹2.24 loss in 3Q 2021). Revenue: ₹308.4m (up 107% from 3Q 2021). Net income: ₹20.3m (up ₹35.4m from 3Q 2021). Profit margin: 6.6% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 10Makers Laboratories Limited Appoints Rinku Kholakiya as the Company Secretary, Compliance OfficerMakers Laboratories Limited at its the Board meeting February 9, 2022 has appointed Ms. Rinku Kholakiya as the Company Secretary, Compliance Officer and Nodal Officer for IEPF of the Company.Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹3.54 (vs ₹1.92 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹341.4m (up 150% from 2Q 2021). Net income: ₹17.4m (up 85% from 2Q 2021). Profit margin: 5.1% (down from 6.9% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.Reported Earnings • Jul 18Full year 2021 earnings released: ₹0.67 loss per share (vs ₹0.25 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: ₹686.4m (up 34% from FY 2020). Net loss: ₹3.29m (loss widened 166% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 136 percentage points per year, which is a significant difference in performance.Reported Earnings • Jun 14Full year 2021 earnings released: EPS ₹2.74 (vs ₹0.25 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹686.4m (up 34% from FY 2020). Net income: ₹13.5m (up ₹14.7m from FY 2020). Profit margin: 2.0% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 14Third quarter 2021 earnings released: ₹2.24 loss per share (vs ₹0.31 loss in 3Q 2020)The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: ₹148.8m (up 32% from 3Q 2020). Net loss: ₹11.0m (loss widened ₹9.45m from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 72% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 04New 90-day high: ₹314The company is up 211% from its price of ₹101 on 06 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.お知らせ • Jan 22Makers Laboratories Limited to Report Q3, 2021 Results on Feb 10, 2021Makers Laboratories Limited announced that they will report Q3, 2021 results on Feb 10, 2021Is New 90 Day High Low • Dec 14New 90-day high: ₹194The company is up 137% from its price of ₹81.60 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 19% share price gain to ₹166, the stock is trading at a trailing P/E ratio of 71.5x, up from the previous P/E ratio of 60.2x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 75%.Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 16% share price gain to ₹144, the stock is trading at a trailing P/E ratio of 62.3x, up from the previous P/E ratio of 53.7x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 64%.Valuation Update With 7 Day Price Move • Nov 12Market bids up stock over the past weekAfter last week's 19% share price gain to ₹118, the stock is trading at a trailing P/E ratio of 50.9x, up from the previous P/E ratio of 42.7x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%.Is New 90 Day High Low • Nov 11New 90-day high: ₹112The company is up 47% from its price of ₹76.30 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Reported Earnings • Nov 06Second quarter 2021 earnings released: EPS ₹1.92The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: ₹137.8m (down 21% from 2Q 2020). Net income: ₹9.42m (up 197% from 2Q 2020). Profit margin: 6.8% (up from 1.8% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Oct 28Makers Laboratories Limited to Report Q2, 2021 Results on Nov 04, 2020Makers Laboratories Limited announced that they will report Q2, 2021 results on Nov 04, 2020Is New 90 Day High Low • Oct 22New 90-day high: ₹108The company is up 70% from its price of ₹63.65 on 24 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.Is New 90 Day High Low • Oct 05New 90-day high: ₹96.60The company is up 95% from its price of ₹49.65 on 07 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period.お知らせ • Sep 30Makers Laboratories Limited (BSE:506919) made an offer to acquire 26% stake in Resonance Specialties Limited (BSE:524218) for approximately 170 million.Makers Laboratories Limited (BSE:506919) made an offer to acquire 26% stake in Resonance Specialties Limited (BSE:524218) for approximately 170 million on September 29, 2020. Under the terms of the transaction, Makers Laboratories made an offer to acquire up to 3,001,440 shares from shareholders of Resonance Specialties at INR 55.5 per share. The Offer Price is payable in cash. In related transactions, Makers Laboratories agreed to acquire 45.48% stake in Resonance Specialties from Ushma Investments Pvt Ltd and Vista Finance & Leasing Private Ltd. through block deal and Kaygee Investments, a person acting in concert agreed to acquire 8.76% stake from Vista Finance & Leasing Private Ltd. through off-market purchase. Prior to these transactions, Makers Laboratories do not hold any stake in Resonance Specialties. On September 29, 2020, the Board of Directors of Makers Laboratories approved this transaction. Amol Kshirsagar and Satish Kumar of Arihant Capital Markets Limited (BSE:511605) acted as financial advisor to the Makers Laboratories.お知らせ • Sep 26Makers Laboratories Limited Announces Resignation of P. M. Kathariya as Independent Director and Member of the Committees of the Board of the CompanyMakers Laboratories Limited announced that Mr. P. M. Kathariya, Independent Director has informed the Company of his inability to continue as a member of the Board of Directors and his intention to resign as the Independent Director/Member of the Committees of the Board of the Company due to his professional pre-occupation as well as personal reasons vide his letter dated September 22, 2020.お知らせ • Aug 13Makers Laboratories Limited Omits Dividend for the Financial Year Ended on March 31, 2020Makers Laboratories Limited announced that the Board of Directors do not recommend dividend for the financial year ended on March 31, 2020.お知らせ • Aug 10Makers Laboratories Limited to Report Q1, 2021 Results on Aug 12, 2020Makers Laboratories Limited announced that they will report Q1, 2021 results on Aug 12, 2020株主還元506919IN PharmaceuticalsIN 市場7D7.7%1.1%0.05%1Y1.8%6.9%-2.0%株主還元を見る業界別リターン: 506919過去 1 年間で6.9 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: 506919過去 1 年間で-2 % の収益を上げたIndian市場を上回りました。価格変動Is 506919's price volatile compared to industry and market?506919 volatility506919 Average Weekly Movement9.3%Pharmaceuticals Industry Average Movement7.2%Market Average Movement7.1%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.7%安定した株価: 506919の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 506919の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1984131Saahil Parikhwww.makerslabs.com総合製薬会社であるメイカーズ・ラボラトリーズ社は、インドで製剤を製造・販売している。同社は、酸調節剤、駆虫剤、抗アレルギー剤、抗喘息剤、抗生物質、抗糖尿病剤、下痢止め、吐き気止め、抗真菌剤、降圧剤、抗炎症剤、鎮痛剤、抗痙攣剤、抗マラリア剤、抗甲状腺剤などの一般健康治療製品を提供している。また、咳止め・風邪薬、消化剤、神経強壮剤、栄養補助食品、局所抗生物質・抗菌剤、その他の特殊医薬品も提供している。同社はDuramol、Artemak-AB、Loroquin、Nimuwin、Coffwin、Exylinのブランド名で製品を販売している。代理店、在庫業者、医師、小売店を通じて製品を販売している。メイカーズ・ラボラトリーズ社は1984年に設立され、インドのムンバイに本社を置いている。もっと見るMakers Laboratories Limited 基礎のまとめMakers Laboratories の収益と売上を時価総額と比較するとどうか。506919 基礎統計学時価総額₹925.47m収益（TTM）₹23.51m売上高(TTM)₹1.42b39.4xPER（株価収益率0.7xP/Sレシオ506919 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計506919 損益計算書（TTM）収益₹1.42b売上原価₹655.74m売上総利益₹767.30mその他の費用₹743.79m収益₹23.51m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）3.99グロス・マージン53.92%純利益率1.65%有利子負債／自己資本比率3.9%506919 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/13 04:19終値2026/06/12 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Makers Laboratories Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Anil BurraFirstCall Research
Reported Earnings • May 27Full year 2026 earnings released: EPS: ₹3.99 (vs ₹12.70 in FY 2025)Full year 2026 results: EPS: ₹3.99 (down from ₹12.70 in FY 2025). Revenue: ₹1.42b (up 18% from FY 2025). Net income: ₹23.5m (down 69% from FY 2025). Profit margin: 1.7% (down from 6.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
お知らせ • May 06Makers Laboratories Limited to Report Q4, 2026 Results on May 26, 2026Makers Laboratories Limited announced that they will report Q4, 2026 results on May 26, 2026
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹922.5m market cap, or US$9.88m). Minor Risk Profit margins are more than 30% lower than last year (0.9% net profit margin).
New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹871.2m market cap, or US$9.61m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).
Reported Earnings • Feb 11Third quarter 2026 earnings released: EPS: ₹1.59 (vs ₹0.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹1.59 (up from ₹0.50 loss in 3Q 2025). Revenue: ₹356.7m (up 29% from 3Q 2025). Net income: ₹9.38m (up ₹12.3m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 21Makers Laboratories Limited to Report Q3, 2026 Results on Feb 10, 2026Makers Laboratories Limited announced that they will report Q3, 2026 results on Feb 10, 2026
Reported Earnings • May 27Full year 2026 earnings released: EPS: ₹3.99 (vs ₹12.70 in FY 2025)Full year 2026 results: EPS: ₹3.99 (down from ₹12.70 in FY 2025). Revenue: ₹1.42b (up 18% from FY 2025). Net income: ₹23.5m (down 69% from FY 2025). Profit margin: 1.7% (down from 6.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
お知らせ • May 06Makers Laboratories Limited to Report Q4, 2026 Results on May 26, 2026Makers Laboratories Limited announced that they will report Q4, 2026 results on May 26, 2026
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹922.5m market cap, or US$9.88m). Minor Risk Profit margins are more than 30% lower than last year (0.9% net profit margin).
New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹871.2m market cap, or US$9.61m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin).
Reported Earnings • Feb 11Third quarter 2026 earnings released: EPS: ₹1.59 (vs ₹0.50 loss in 3Q 2025)Third quarter 2026 results: EPS: ₹1.59 (up from ₹0.50 loss in 3Q 2025). Revenue: ₹356.7m (up 29% from 3Q 2025). Net income: ₹9.38m (up ₹12.3m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 21Makers Laboratories Limited to Report Q3, 2026 Results on Feb 10, 2026Makers Laboratories Limited announced that they will report Q3, 2026 results on Feb 10, 2026
New Risk • Nov 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹748.2m market cap, or US$8.44m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Reported Earnings • Nov 08Second quarter 2026 earnings released: ₹0.20 loss per share (vs ₹14.94 profit in 2Q 2025)Second quarter 2026 results: ₹0.20 loss per share (down from ₹14.94 profit in 2Q 2025). Revenue: ₹345.3m (up 17% from 2Q 2025). Net loss: ₹1.17m (down 101% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Oct 16Makers Laboratories Limited to Report Q2, 2026 Results on Nov 07, 2025Makers Laboratories Limited announced that they will report Q2, 2026 results on Nov 07, 2025
Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.74 (vs ₹1.67 loss in 1Q 2025)First quarter 2026 results: EPS: ₹0.74 (up from ₹1.67 loss in 1Q 2025). Revenue: ₹352.7m (up 19% from 1Q 2025). Net income: ₹4.37m (up ₹14.2m from 1Q 2025). Profit margin: 1.2% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
New Risk • Jul 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹867.9m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$10m (₹867.9m market cap, or US$9.99m). Minor Risk Large one-off items impacting financial results.
お知らせ • Jul 25Makers Laboratories Limited to Report Q1, 2026 Results on Aug 08, 2025Makers Laboratories Limited announced that they will report Q1, 2026 results at 9:15 AM, Indian Standard Time on Aug 08, 2025
Reported Earnings • Jul 10Full year 2025 earnings released: EPS: ₹12.70 (vs ₹10.62 loss in FY 2024)Full year 2025 results: EPS: ₹12.70 (up from ₹10.62 loss in FY 2024). Revenue: ₹1.21b (up 16% from FY 2024). Net income: ₹74.9m (up ₹137.5m from FY 2024). Profit margin: 6.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 02Makers Laboratories Limited, Annual General Meeting, Aug 08, 2025Makers Laboratories Limited, Annual General Meeting, Aug 08, 2025, at 12:30 Indian Standard Time.
New Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹850.2m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$10m (₹850.2m market cap, or US$9.80m).
Reported Earnings • May 28Full year 2025 earnings released: EPS: ₹12.70 (vs ₹10.62 loss in FY 2024)Full year 2025 results: EPS: ₹12.70 (up from ₹10.62 loss in FY 2024). Revenue: ₹1.33b (up 27% from FY 2024). Net income: ₹74.9m (up ₹137.5m from FY 2024). Profit margin: 5.6% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
New Risk • May 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹814.5m market cap, or US$9.52m).
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹165, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 2.1% over the past three years.
お知らせ • May 13Makers Laboratories Limited to Report Q4, 2025 Results on May 26, 2025Makers Laboratories Limited announced that they will report Q4, 2025 results at 9:15 AM, Indian Standard Time on May 26, 2025
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹126, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total loss to shareholders of 28% over the past three years.
New Risk • Feb 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹856.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (₹856.4m market cap, or US$9.85m).
Reported Earnings • Jan 31Third quarter 2025 earnings released: ₹0.50 loss per share (vs ₹2.61 loss in 3Q 2024)Third quarter 2025 results: ₹0.50 loss per share (improved from ₹2.61 loss in 3Q 2024). Revenue: ₹276.9m (up 4.4% from 3Q 2024). Net loss: ₹2.97m (loss narrowed 81% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 14Makers Laboratories Limited to Report Q3, 2025 Results on Jan 29, 2025Makers Laboratories Limited announced that they will report Q3, 2025 results on Jan 29, 2025
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹219, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past three years.
New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹976.5m market cap, or US$11.5m).
Reported Earnings • Oct 30Second quarter 2025 earnings released: EPS: ₹14.94 (vs ₹2.27 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹14.94 (up from ₹2.27 loss in 2Q 2024). Revenue: ₹400.8m (up 60% from 2Q 2024). Net income: ₹88.2m (up ₹101.6m from 2Q 2024). Profit margin: 22% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 17Makers Laboratories Limited to Report Q2, 2025 Results on Oct 29, 2024Makers Laboratories Limited announced that they will report Q2, 2025 results on Oct 29, 2024
New Risk • Oct 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹806.6m (US$9.61m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 54% per year over the past 5 years. Market cap is less than US$10m (₹806.6m market cap, or US$9.61m).
New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 54% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹888.0m market cap, or US$10.6m).
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 54% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₹989.8m market cap, or US$11.8m).
お知らせ • Jul 22Makers Laboratories Limited to Report Q1, 2025 Results on Aug 06, 2024Makers Laboratories Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 06, 2024
Reported Earnings • Jul 13Full year 2024 earnings released: ₹10.62 loss per share (vs ₹7.90 loss in FY 2023)Full year 2024 results: ₹10.62 loss per share (further deteriorated from ₹7.90 loss in FY 2023). Revenue: ₹1.04b (up 3.1% from FY 2023). Net loss: ₹62.6m (loss widened 32% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 06Makers Laboratories Limited, Annual General Meeting, Aug 06, 2024Makers Laboratories Limited, Annual General Meeting, Aug 06, 2024, at 11:30 Indian Standard Time.
Reported Earnings • May 24Full year 2024 earnings released: ₹10.62 loss per share (vs ₹7.90 loss in FY 2023)Full year 2024 results: ₹10.62 loss per share (further deteriorated from ₹7.90 loss in FY 2023). Revenue: ₹1.06b (up 4.6% from FY 2023). Net loss: ₹62.6m (loss widened 32% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
お知らせ • May 09Makers Laboratories Limited to Report Q4, 2024 Results on May 23, 2024Makers Laboratories Limited announced that they will report Q4, 2024 results on May 23, 2024
お知らせ • Feb 15Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024Makers Laboratories Limited announced the resignation of Ms. Surbhi Sharma as Company Secretary /Compliance Officer. Date of Cessation is March 13, 2024.
Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹2.61 loss per share (vs ₹3.65 loss in 3Q 2023)Third quarter 2024 results: ₹2.61 loss per share (improved from ₹3.65 loss in 3Q 2023). Revenue: ₹268.8m (up 35% from 3Q 2023). Net loss: ₹15.4m (loss narrowed 30% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 23Makers Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024Makers Laboratories Limited announced that they will report Q3, 2024 results at 12:15 PM, Indian Standard Time on Feb 13, 2024
Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Additional Non-Executive Independent Director Vishal Jain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 09Second quarter 2024 earnings released: ₹2.27 loss per share (vs ₹1.00 loss in 2Q 2023)Second quarter 2024 results: ₹2.27 loss per share (further deteriorated from ₹1.00 loss in 2Q 2023). Revenue: ₹250.6m (down 5.4% from 2Q 2023). Net loss: ₹13.4m (loss widened 108% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 20Makers Laboratories Limited to Report Q2, 2023 Results on Nov 07, 2023Makers Laboratories Limited announced that they will report Q2, 2023 results on Nov 07, 2023
Reported Earnings • Aug 16First quarter 2024 earnings released: ₹3.55 loss per share (vs ₹2.82 loss in 1Q 2023)First quarter 2024 results: ₹3.55 loss per share (further deteriorated from ₹2.82 loss in 1Q 2023). Revenue: ₹252.5m (flat on 1Q 2023). Net loss: ₹21.0m (loss widened 30% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 26Makers Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023Makers Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Reported Earnings • Jul 13Full year 2023 earnings released: ₹7.90 loss per share (vs ₹10.13 profit in FY 2022)Full year 2023 results: ₹7.90 loss per share (down from ₹10.13 profit in FY 2022). Revenue: ₹1.01b (down 21% from FY 2022). Net loss: ₹47.5m (down 195% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
お知らせ • Jul 06Makers Laboratories Limited, Annual General Meeting, Aug 14, 2023Makers Laboratories Limited, Annual General Meeting, Aug 14, 2023, at 11:30 Indian Standard Time.
Reported Earnings • May 24Full year 2023 earnings released: ₹7.90 loss per share (vs ₹10.13 profit in FY 2022)Full year 2023 results: ₹7.90 loss per share (down from ₹10.13 profit in FY 2022). Revenue: ₹1.04b (down 19% from FY 2022). Net loss: ₹47.5m (down 195% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 14Third quarter 2023 earnings released: ₹3.65 loss per share (vs ₹4.13 profit in 3Q 2022)Third quarter 2023 results: ₹3.65 loss per share (down from ₹4.13 profit in 3Q 2022). Revenue: ₹201.4m (down 32% from 3Q 2022). Net loss: ₹22.1m (down 209% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.
お知らせ • Jan 21Makers Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023Makers Laboratories Limited announced that they will report Q3, 2023 results on Feb 13, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: ₹1.00 loss per share (vs ₹3.54 profit in 2Q 2022)Second quarter 2023 results: ₹1.00 loss per share (down from ₹3.54 profit in 2Q 2022). Revenue: ₹273.8m (down 18% from 2Q 2022). Net loss: ₹6.44m (down 137% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year.
お知らせ • Nov 01Makers Laboratories Limited Announces Resignation of Rinku Kholakiya as Company SecretaryMakers Laboratories Limited informed that Ms. Rinku Kholakiya, Company Secretary has resigned from the services of the Company with effect from close of business hours on 31st October, 2022 and accordingly, she will cease to be the Company Secretary and Key Managerial Personnel of the company from 1st November, 2022.
お知らせ • Oct 20Makers Laboratories Limited to Report Q2, 2022 Results on Nov 14, 2022Makers Laboratories Limited announced that they will report Q2, 2022 results on Nov 14, 2022
Reported Earnings • Aug 14First quarter 2023 earnings released: ₹2.82 loss per share (vs ₹3.69 profit in 1Q 2022)First quarter 2023 results: ₹2.82 loss per share (down from ₹3.69 profit in 1Q 2022). Revenue: ₹264.6m (down 27% from 1Q 2022). Net loss: ₹16.2m (down 189% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 30Makers Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Makers Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022
Reported Earnings • Jul 16Full year 2022 earnings released: EPS: ₹10.12 (vs ₹0.67 loss in FY 2021)Full year 2022 results: EPS: ₹10.12 (up from ₹0.67 loss in FY 2021). Revenue: ₹1.30b (up 89% from FY 2021). Net income: ₹49.8m (up ₹53.1m from FY 2021). Profit margin: 3.8% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 09Makers Laboratories Limited, Annual General Meeting, Aug 12, 2022Makers Laboratories Limited, Annual General Meeting, Aug 12, 2022, at 11:30 Indian Standard Time.
お知らせ • May 17Makers Laboratories Limited to Report Q4, 2022 Results on May 27, 2022Makers Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022
Reported Earnings • Feb 10Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹4.13 (up from ₹2.24 loss in 3Q 2021). Revenue: ₹308.4m (up 107% from 3Q 2021). Net income: ₹20.3m (up ₹35.4m from 3Q 2021). Profit margin: 6.6% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 10Makers Laboratories Limited Appoints Rinku Kholakiya as the Company Secretary, Compliance OfficerMakers Laboratories Limited at its the Board meeting February 9, 2022 has appointed Ms. Rinku Kholakiya as the Company Secretary, Compliance Officer and Nodal Officer for IEPF of the Company.
Reported Earnings • Nov 12Second quarter 2022 earnings released: EPS ₹3.54 (vs ₹1.92 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹341.4m (up 150% from 2Q 2021). Net income: ₹17.4m (up 85% from 2Q 2021). Profit margin: 5.1% (down from 6.9% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.
Reported Earnings • Jul 18Full year 2021 earnings released: ₹0.67 loss per share (vs ₹0.25 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: ₹686.4m (up 34% from FY 2020). Net loss: ₹3.29m (loss widened 166% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 136 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jun 14Full year 2021 earnings released: EPS ₹2.74 (vs ₹0.25 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹686.4m (up 34% from FY 2020). Net income: ₹13.5m (up ₹14.7m from FY 2020). Profit margin: 2.0% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 14Third quarter 2021 earnings released: ₹2.24 loss per share (vs ₹0.31 loss in 3Q 2020)The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: ₹148.8m (up 32% from 3Q 2020). Net loss: ₹11.0m (loss widened ₹9.45m from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 72% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 04New 90-day high: ₹314The company is up 211% from its price of ₹101 on 06 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
お知らせ • Jan 22Makers Laboratories Limited to Report Q3, 2021 Results on Feb 10, 2021Makers Laboratories Limited announced that they will report Q3, 2021 results on Feb 10, 2021
Is New 90 Day High Low • Dec 14New 90-day high: ₹194The company is up 137% from its price of ₹81.60 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 19% share price gain to ₹166, the stock is trading at a trailing P/E ratio of 71.5x, up from the previous P/E ratio of 60.2x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 75%.
Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 16% share price gain to ₹144, the stock is trading at a trailing P/E ratio of 62.3x, up from the previous P/E ratio of 53.7x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 64%.
Valuation Update With 7 Day Price Move • Nov 12Market bids up stock over the past weekAfter last week's 19% share price gain to ₹118, the stock is trading at a trailing P/E ratio of 50.9x, up from the previous P/E ratio of 42.7x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%.
Is New 90 Day High Low • Nov 11New 90-day high: ₹112The company is up 47% from its price of ₹76.30 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Reported Earnings • Nov 06Second quarter 2021 earnings released: EPS ₹1.92The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: ₹137.8m (down 21% from 2Q 2020). Net income: ₹9.42m (up 197% from 2Q 2020). Profit margin: 6.8% (up from 1.8% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Oct 28Makers Laboratories Limited to Report Q2, 2021 Results on Nov 04, 2020Makers Laboratories Limited announced that they will report Q2, 2021 results on Nov 04, 2020
Is New 90 Day High Low • Oct 22New 90-day high: ₹108The company is up 70% from its price of ₹63.65 on 24 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.
Is New 90 Day High Low • Oct 05New 90-day high: ₹96.60The company is up 95% from its price of ₹49.65 on 07 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period.
お知らせ • Sep 30Makers Laboratories Limited (BSE:506919) made an offer to acquire 26% stake in Resonance Specialties Limited (BSE:524218) for approximately 170 million.Makers Laboratories Limited (BSE:506919) made an offer to acquire 26% stake in Resonance Specialties Limited (BSE:524218) for approximately 170 million on September 29, 2020. Under the terms of the transaction, Makers Laboratories made an offer to acquire up to 3,001,440 shares from shareholders of Resonance Specialties at INR 55.5 per share. The Offer Price is payable in cash. In related transactions, Makers Laboratories agreed to acquire 45.48% stake in Resonance Specialties from Ushma Investments Pvt Ltd and Vista Finance & Leasing Private Ltd. through block deal and Kaygee Investments, a person acting in concert agreed to acquire 8.76% stake from Vista Finance & Leasing Private Ltd. through off-market purchase. Prior to these transactions, Makers Laboratories do not hold any stake in Resonance Specialties. On September 29, 2020, the Board of Directors of Makers Laboratories approved this transaction. Amol Kshirsagar and Satish Kumar of Arihant Capital Markets Limited (BSE:511605) acted as financial advisor to the Makers Laboratories.
お知らせ • Sep 26Makers Laboratories Limited Announces Resignation of P. M. Kathariya as Independent Director and Member of the Committees of the Board of the CompanyMakers Laboratories Limited announced that Mr. P. M. Kathariya, Independent Director has informed the Company of his inability to continue as a member of the Board of Directors and his intention to resign as the Independent Director/Member of the Committees of the Board of the Company due to his professional pre-occupation as well as personal reasons vide his letter dated September 22, 2020.
お知らせ • Aug 13Makers Laboratories Limited Omits Dividend for the Financial Year Ended on March 31, 2020Makers Laboratories Limited announced that the Board of Directors do not recommend dividend for the financial year ended on March 31, 2020.
お知らせ • Aug 10Makers Laboratories Limited to Report Q1, 2021 Results on Aug 12, 2020Makers Laboratories Limited announced that they will report Q1, 2021 results on Aug 12, 2020
